Quality of Recovery From Obstetric Anaesthesia - a Multicentre Study (ObsQoR)

Quality of recovery is an important outcome measure in anaesthesia, whilst there are validated tools for this in surgery and regional anesthesia there are no fully validated tools for obstetrics anaesthesia. The aim of this study is to use the Obstetric Quality of Recovery (ObsQoR) score across multiple centres to assess correlation to length of stay and variation for different types of operative and non- operative delivery.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

An observational survey based study, for 3 consecutive week days, chosen by the local investigating team during a two-week period across multiple centres.

  • Local investigators will complete the survey with each patient who has received anaesthetic intervention from an anaesthetist, 1 day, around 24hrs after delivery in line with their routine anaesthetic follow up.
  • At 30 days, a telephone survey will be conducted with each patient to repeat the ObsQoR survey and ask key questions regarding functional recovery and activities of daily living post delivery.

In addition for a small number of sites, elective caesarean delivery patients will have blood taken at the point of anaesthesia and 24 hours post delivery to assess the immune function and any changes which may predict poorer outcome in these women.

Study Type

Observational

Enrollment (Actual)

1638

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • London, United Kingdom, SE1 7RT
        • Guy's and St Thomas' NHS Foundation Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Peripartum women during the designated study period who have received anaesthetic intervention in the previous 24-hour period for 3 consecutive days.

Description

Inclusion Criteria:

  • Obstetric patients over 18 years old.
  • Intervention occurring after 32/40 gestation.
  • All mothers receiving anaesthesia or anaesthetic analgesia during their peripartum period.

Exclusion Criteria:

  • Unable to comprehend the questions asked
  • Patient refusal
  • Under 32/40 weeks gestation
  • Cervical cerclage insertion or removal, anaesthesia for External Cephalic Verison
  • Neonatal death
  • Non- NHS patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
• Correlation of ObsQoR with length of hospital stay (LOS) in hours following delivery across multiple centres, particularly ObsQoR score and prediction of prolonged LOS (>1.5 SD) and readmission to hospital.
Time Frame: Up to 3 months
During the study the total length of stay in hours will be calculated for participating patients. This will be correlated with the score from the ObsQoR survey tool. In addition the readmission status of the patient will be asked at the subsequent survey combined with the patient's health care record to correlate with the ObsQoR tool score. Where the ObsQoR score is measured between 0-100 and LOS will be in hours. Readmission will be a binary outcome measure
Up to 3 months
• The relationship between ObsQoR and patient-reported ready for discharge. This will concurrently be determined to account for institutional, non-medical maternal factors neonatal factors that may delay discharge and impact LOS.
Time Frame: up to 3 months
The patient will be surveyed using the ObsQoR tool and also asked regarding when they felt they were ready for discharge to take into account the multitude of factors which may impact on the overall length of stay. Where the ObsQoR score is measured between 0-100 and LOS will be in hours.
up to 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
• Comparing ObsQoR profiles with differing types of obstetric anaesthesia and delivery method.
Time Frame: up to 3 months
ObsQoR tool will be used to assess the quality of recovery from General anaesthesia and differing types of regional anaesthesia (Spinal, Epidural, Dural puncture epidural (DPE) and combined spinal and epidural (CSE)
up to 3 months
• Variations in ObsQoR scores across differing centres.
Time Frame: up to 3 months
A multicentreed evaluation of the ObsQoR score across multiple centres
up to 3 months
• Impact of patient factors on ObsQoR score.
Time Frame: up to 3 months
A large number of variables will affect the quality of recovery and the ObsQoR score, these factors will be assessed. Where the ObsQoR score is measured between 0-100
up to 3 months
• Impact of anaesthetic or obstetric factors on ObsQoR score.
Time Frame: up to 3 months
A large number of variables will affect the quality of recovery and the ObsQoR score, these factors will be assessed. Where the ObsQoR score is measured between 0-100
up to 3 months
• Impact of neonatal facts on ObsQoR score.
Time Frame: up to 3 months
A large number of variables will affect the quality of recovery and the ObsQoR score, these factors will be assessed. Where the ObsQoR score is measured between 0-100
up to 3 months
• Impact of institutional factors on ObsQoR score.
Time Frame: up to 3 months
Differing centres will have differing institutional setup, guidelines, staffing levels, these will be assessed related to ObsQoR scores. Where the ObsQoR score is measured between 0-100
up to 3 months
• Impact of time of day on ObsQoR score.
Time Frame: up to 3 months
Time of day may impact on patient care on the quality of recover and the ObsQoR score- these will both be assessed. Where the ObsQoR score is measured between 0-100
up to 3 months
• Impact of anaesthesia provider factors on ObsQoR score.
Time Frame: up to 3 months
The level of seniority of anaesthesia provider may impact on the quality of recover and the ObsQoR score- these will both be assessed. Where the ObsQoR score is measured between 0-100
up to 3 months
• Prediction of patients who are likely to have an ongoing requirement for analgesia.
Time Frame: up to 3 months
The varying delivery methods have differing requirements for analgesia, it is not currently known the impact and effect this has on the quality of recovery. Where the ObsQoR score is measured between 0-100
up to 3 months
• Prediction of patients who are likely to require further follow up in the community or investigation.
Time Frame: up to 3 months
The patient surgical social and institutional demographics which may predispose some patients to seek healthcare in either the community or hospital setting
up to 3 months
• Prediction of patients' ability to return to normal activities of daily living.
Time Frame: up to 3 months
Functional recovery will be assessed observing return to normal activities of daily living (ADLs) and compared to ObsQoR score for patients of all delivery types. The score of ADLs will be correlated to ObsQoR score Where the ObsQoR score is measured between 0-100
up to 3 months
• Prediction of patients' who are unable to achieve adequate activity levels. As determined by number of steps on mobile phone / activity tracker.
Time Frame: up to 3 months
Assessment of the number of steps and related to quality of recovery and return to normal activities of daily living. Where steps will be a continuous measure and ObsQoR score will be measured from 0-100.
up to 3 months
Assessment of perioperative immune function and response to surgical trauma as a predictor of outcome following elective caesarean delivery.
Time Frame: up to 3 months
this will be assessed by taking bloods at the point of anaesthesia and 24 hours post in selected patients undergoing a elective caesarean delivery. The samples will then be analysed to assess the immune response.
up to 3 months
Assessment of correlation between ObsQoR scores, EQ-5D and global health visual analogue scale results at 24 hours and 30 days.
Time Frame: up to 30 days
Assessment of the relationship between ObsQoR scores at 24 hours with EQ-5D and global VAS scores at 24 hours and 30 days between different patients modes of anaesthesia, delivery types and institutions. Assessment of the relationship patient reported outcome measures PROMs to objective poor recovery such as, length of stay, complications and readmissions
up to 30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Study Chair: Kariem El-Boghdadly, GSTT

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 11, 2021

Primary Completion (Actual)

October 24, 2021

Study Completion (Actual)

November 24, 2021

Study Registration Dates

First Submitted

November 8, 2019

First Submitted That Met QC Criteria

December 6, 2019

First Posted (Actual)

December 10, 2019

Study Record Updates

Last Update Posted (Actual)

June 15, 2022

Last Update Submitted That Met QC Criteria

June 14, 2022

Last Verified

June 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • IRAS254064

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

The raw data will be available on request at the discretion of the central study team

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Quality of Life

Clinical Trials on Survey

Subscribe